Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York StateAUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH) ...
(NASDAQ: NEO), a leading oncology testing services company, today announced that the New York State Department of Health (NYSDOH) has granted the company conditional approval for its Neo Comprehensive ...
Aspira Women's Health has received approval from the New York State Department of Health's (NYDOH) Clinical Laboratory Evaluation Program (CLEP) to market its ovarian cancer test OvaWatch in New York, ...